Verrica Pharmaceuticals stock gets a Buy rating from Lake Street

Verrica Pharmaceuticals (ISIN US92511W2070) closed at USD 4.21 on Nasdaq on October 7, 2026, down 2.32 percent from the prior close. The latest analyst action came from Lake Street, which maintained its Buy rating on October 5, 2026, according to The Globe and Mail.

Lake Street keeps Buy rating

Lake Street's rating decision followed Verrica's second-quarter results for the period ended June 30, 2026. The company reported revenue of USD 5.862 million and a GAAP net loss of USD 13.153 million, or USD 0.62 per diluted share, according to The Globe and Mail.

The revenue figure was lower than the year-earlier quarter because the comparison included an USD 8 million milestone recorded in the second quarter of 2025. U.S. YCANTH net product revenue reached USD 5.1 million in the second quarter, while dispensed applicator units rose to 19,626, up 28.3 percent from the first quarter, according to the same October 5 report.

YCANTH data adds a clinical angle

Verrica is presenting a pooled post-hoc analysis of the CAMP-1 and CAMP-2 Phase 3 trials for YCANTH, its treatment for molluscum contagiosum. The analysis found a hazard ratio of 4.06 for complete clearance versus vehicle, with a 95 percent confidence interval of 2.94 to 5.74, according to Associated Press. By Day 84, complete clearance reached 60.1 percent with VP-102 versus 19.9 percent with vehicle.

The company is presenting the analysis at the Fall Clinical Dermatology Conference from October 8 through October 11, 2026, and plans a further presentation at the PeDRA Annual Conference beginning October 15, 2026, according to Associated Press. The dates give investors a near-term checkpoint for new clinical detail while YCANTH remains the company's marketed product.

Consensus target stays above USD 12

MarketBeat lists a Hold consensus based on five analyst ratings, including three Buys, one Hold and one Sell. Its average price target is USD 12.67, which lies 200.9 percent above the October 7 closing price of USD 4.21.

That valuation gap places the analyst view alongside a demanding operating picture: second-quarter operating cash flow was negative USD 9.278 million, and cash stood at USD 11.198 million on June 30, 2026. For investors, the key balance is commercial adoption of YCANTH against continued cash use during development of VP-315.

Verrica stock remains below its yearly high

Verrica stock closed at USD 4.21 on Nasdaq on October 7, 2026. The 52-week range was USD 3.28 to USD 9.82, while market capitalization stood at USD 71.1 million and volume reached 47,552 shares on that date.

More news and analyses on Verrica Pharmaceuticals stock